133 related articles for article (PubMed ID: 27177523)
41. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
42. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
43. A Phase I Clinical Trial to Assess Safety and Tolerability of Injectable Collagenase in Women with Symptomatic Uterine Fibroids.
Singh B; Sims H; Trueheart I; Simpson K; Wang KC; Patzkowsky K; Wegman T; Soma JM; Dixon R; Jayes F; Voegltine K; Yenokyan G; Su SC; Leppert P; Segars JH
Reprod Sci; 2021 Sep; 28(9):2699-2709. PubMed ID: 33914296
[TBL] [Abstract][Full Text] [Related]
44. Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach).
Vafaei S; Ciebiera M; Omran MM; Ghasroldasht MM; Yang Q; Leake T; Wolfe R; Ali M; Al-Hendy A
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958957
[TBL] [Abstract][Full Text] [Related]
45. Update on the Role and Regulatory Mechanism of Extracellular Matrix in the Pathogenesis of Uterine Fibroids.
Yang Q; Al-Hendy A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982852
[TBL] [Abstract][Full Text] [Related]
46. Joint Secondary Transcriptomic Analysis of Non-Hodgkin's B-Cell Lymphomas Predicts Reliance on Pathways Associated with the Extracellular Matrix and Robust Diagnostic Biomarkers.
Rapier-Sharman N; Clancy J; Pickett BE
J Bioinform Syst Biol; 2022; 5(4):119-135. PubMed ID: 36873459
[TBL] [Abstract][Full Text] [Related]
47. Linear and nonlinear rheology of liberase-treated breast cancer tumors.
Corder RD; Vachieri RB; Martin ME; Taylor DK; Fleming JM; Khan SA
Biomater Sci; 2023 Mar; 11(6):2186-2199. PubMed ID: 36744734
[TBL] [Abstract][Full Text] [Related]
48. Biomechanical Forces Determine Fibroid Stem Cell Transformation and the Receptivity Status of the Endometrium: A Critical Appraisal.
Celik O; Celik N; Gungor ND; Celik S; Arslan L; Morciano A; Tinelli A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430682
[TBL] [Abstract][Full Text] [Related]
49. Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues.
Dooling LJ; Saini K; Anlaş AA; Discher DE
Matrix Biol; 2022 Aug; 111():153-188. PubMed ID: 35764212
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment.
Yang Q; Ciebiera M; Bariani MV; Ali M; Elkafas H; Boyer TG; Al-Hendy A
Endocr Rev; 2022 Jul; 43(4):678-719. PubMed ID: 34741454
[TBL] [Abstract][Full Text] [Related]
51. Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion.
Corder RD; Gadi SV; Vachieri RB; Jayes FL; Cullen JM; Khan SA; Taylor DK
Acta Biomater; 2021 Oct; 134():443-452. PubMed ID: 34371168
[TBL] [Abstract][Full Text] [Related]
52. Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids.
Islam MS; Afrin S; Singh B; Jayes FL; Brennan JT; Borahay MA; Leppert PC; Segars JH
Clin Transl Med; 2021 Jul; 11(7):e475. PubMed ID: 34323413
[TBL] [Abstract][Full Text] [Related]
53. Summary of the Proceedings of the Basic Science of Uterine Fibroids Meeting: New Developments February 28, 2020.
Leppert PC; Al-Hendy A; Baird DD; Bulun S; Catherino W; Dixon D; Ducharme M; Harmon QE; Jayes FL; Paul E; Perucho AM; Segars J; Simón C; Stewart EA; Teixeira J; Tinelli A; Tschumperlin D; Zota AR
F S Sci; 2021 Feb; 2(1):88-100. PubMed ID: 34124698
[TBL] [Abstract][Full Text] [Related]
54. Nano-Scale Stiffness and Collagen Fibril Deterioration: Probing the Cornea Following Enzymatic Degradation Using Peakforce-QNM AFM.
Kazaili A; Abdul-Amir Al-Hindy H; Madine J; Akhtar R
Sensors (Basel); 2021 Feb; 21(5):. PubMed ID: 33652583
[TBL] [Abstract][Full Text] [Related]
55. Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas.
Khan KN; Fujishita A; Koshiba A; Ogawa K; Mori T; Ogi H; Itoh K; Teramukai S; Kitawaki J
PLoS One; 2020; 15(11):e0242246. PubMed ID: 33186388
[TBL] [Abstract][Full Text] [Related]
56. The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids.
Ciebiera M; Ali M; Prince L; Jackson-Bey T; Atabiekov I; Zgliczyński S; Al-Hendy A
J Clin Med; 2020 May; 9(5):. PubMed ID: 32423112
[TBL] [Abstract][Full Text] [Related]
57. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
58. Advanced 3D Imaging of Uterine Leiomyoma's Morphology by Propagation-based Phase-Contrast Microtomography.
Giuliani A; Greco S; Pacilè S; Zannotti A; Delli Carpini G; Tromba G; Giannubilo SR; Ciavattini A; Ciarmela P
Sci Rep; 2019 Jul; 9(1):10580. PubMed ID: 31332223
[TBL] [Abstract][Full Text] [Related]
59. Ex vivo pregnant-like tissue model to assess injectable hydrogel for preterm birth prevention.
Raia NR; Bakaysa SL; Ghezzi CE; House MD; Kaplan DL
J Biomed Mater Res B Appl Biomater; 2020 Feb; 108(2):468-474. PubMed ID: 31070848
[TBL] [Abstract][Full Text] [Related]
60. Evidence of biomechanical and collagen heterogeneity in uterine fibroids.
Jayes FL; Liu B; Feng L; Aviles-Espinoza N; Leikin S; Leppert PC
PLoS One; 2019; 14(4):e0215646. PubMed ID: 31034494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
